Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Kim N., Rathkopf, Dana, Smith, Matthew R., Efstathiou, Eleni, Attard, Gerhardt, Olmos, David, Lee, Ji Youl, Small, Eric J., Pereira de Santana Gomes, Andrea J., Roubaud, Guilhem, Saad, Marniza, Zurawski, Bogdan, Sakalo, Valerii, Mason, Gary E., Francis, Peter, Wang, George, Wu, Daphne, Diorio, Brooke, Lopez-Gitlitz, Angela, Sandhu, Shahneen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431499/
https://www.ncbi.nlm.nih.gov/pubmed/36952634
http://dx.doi.org/10.1200/JCO.22.01649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431499/
https://www.ncbi.nlm.nih.gov/pubmed/36952634
http://dx.doi.org/10.1200/JCO.22.01649

Ejemplares similares